DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative
oncology and cardiovascular surgical and diagnostic products, today
announced it would report its financial results for the third quarter of
2006 on Thursday, November 2, 2006 after the close of the financial
markets. The announcement will be followed by a conference call
scheduled for the next morning, Friday, November 3, 2006, with the
investment community at 10:00 AM EST.
Neoprobe’s President and CEO, David Bupp, and
Vice President and CFO, Brent Larson, will provide a business update and
discuss the company’s results for the third
quarter of 2006 during the conference call scheduled for 10:00 AM EST,
Friday, November 3, 2006. The conference call can be accessed as follows:
Neoprobe is a biomedical company focused on enhancing patient care and
improving patient outcome by meeting the critical intraoperative
diagnostic information needs of physicians and therapeutic treatment
needs of patients. Neoprobe currently markets the neo2000®
line of gamma detection systems that are widely used by cancer surgeons
and is commercializing the Quantix®
line of blood flow measurement products developed by its subsidiary,
Cardiosonix Ltd. In addition, Neoprobe holds significant interests in
the development of related biomedical systems and radiopharmaceutical
agents including Lymphoseek™ and RIGScan®
CR. Neoprobe’s subsidiary, Cira Biosciences,
Inc., is also advancing a patient-specific cellular therapy technology
platform called ACT. Neoprobe’s strategy is to
deliver superior growth and shareholder return by maximizing its strong
position in gamma detection technologies and diversifying into new,
synergistic biomedical markets through continued investment and
selective acquisitions. www.neoprobe.com
